Related Experiment Videos
[Neutropenia from oxacillin. 3 pediatric cases]
Pediatrie
|September 1, 1984
Abstract:
Neutropenia developed in 3 pediatrics patients during treatment with oxacillin. The time of onset ranged from 18 to 24 days after beginning treatment with dose of 150 mg/kg/24 h. Concomitant symptoms were fever and rashes. During treatment with oxacillin it is necessary to monitor blood cell count every week.
Insights
Oxacillin treatment can cause neutropenia (low white blood cell count) in children, appearing 18-24 days into therapy. Monitor blood cell counts weekly during oxacillin use to detect this adverse effect.
Area of Science:
- Pediatric Hematology
- Clinical Pharmacology
- Infectious Diseases
Background:
- Oxacillin is a penicillinase-resistant penicillin antibiotic commonly used to treat bacterial infections, particularly those caused by Staphylococcus species.
- Neutropenia, a condition characterized by abnormally low levels of neutrophils, can increase the risk of infection.
- Adverse drug reactions in pediatric populations require careful monitoring and documentation.
Observation:
- Three pediatric patients developed neutropenia during treatment with oxacillin.
- The onset of neutropenia occurred between 18 and 24 days after initiating oxacillin therapy at a dosage of 150 mg/kg/24 h.
- Associated symptoms included fever and skin rashes, suggesting a potential hypersensitivity or toxic reaction.
Findings:
- Oxacillin administration was associated with the development of neutropenia in pediatric patients.
- The timing of neutropenia suggests a subacute or delayed reaction to the antibiotic.
- Concurrent fever and rashes may serve as clinical indicators of this adverse event.
Implications:
- Weekly monitoring of complete blood counts is crucial for pediatric patients receiving oxacillin to enable early detection of neutropenia.
- Healthcare providers should be vigilant for signs of neutropenia, such as fever and rash, in children treated with oxacillin.
- This finding highlights the importance of pharmacovigilance for antibiotics in pediatric populations to ensure patient safety and optimize treatment outcomes.